NYUAD Researchers Identify the Code That Regulates Liver Regrowth: A New Form of Regenerative Medicine May Follow
source: pixabay.com

NYUAD Researchers Identify the Code That Regulates Liver Regrowth: A New Form of Regenerative Medicine May Follow

  Researchers at NYU Abu Dhabi (NYUAD) have discovered the code that is associated with the liver’s genome (complete set of DNA) and its ability to regenerate. According to a…

Continue Reading NYUAD Researchers Identify the Code That Regulates Liver Regrowth: A New Form of Regenerative Medicine May Follow
Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment
source: pixabay.com

Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment

Albireo has recently initiated their Phase 3 ASSERT trial, according to GlobeNewswire. This study will evaluate odevixibat as a treatment for Alagille syndrome. This therapy fits well with Albireo's mission,…

Continue Reading Initiation of Global Phase 3 Trial of Alagille Syndrome Treatment
HemoShear & Takeda Partnership Identifies New Drug Target for NASH
source: pixabay.com

HemoShear & Takeda Partnership Identifies New Drug Target for NASH

In a recent press release, biotechnology company HemoShear Therapeutics ("HemoShear") shared that the company, in collaboration with Takeda Pharmaceutical Company Ltd. ("Takeda") identified a novel therapeutic target for nonalcoholic steatohepatitis…

Continue Reading HemoShear & Takeda Partnership Identifies New Drug Target for NASH
New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease
source: pixabay.com

New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease

  In October 2020, Arrowhead Pharmaceuticals ("Arrowhead") announced a new collaboration and licensing agreement with global biopharmaceutical company Takeda Pharmaceutical Company Limited ("Takeda"). Together, the pair will develop and commercialize…

Continue Reading New Collaboration Will Develop ARO-AAT for A1AD-Related Liver Disease
FDA Grants Orphan Drug Designation for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency
kalhh / Pixabay

FDA Grants Orphan Drug Designation for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency

Dicerna Pharmaceuticals works in ribonucleic interference (RNAi) therapies as treatments of rare diseases. They have recently been granted the orphan drug designation by the European Commission for their drug, DCR-A1AT.…

Continue Reading FDA Grants Orphan Drug Designation for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency
The Good-News-Bad-News Basics of Fatty Liver Disease and NASH
https://pixabay.com/en/bundle-jute-rope-newspaper-1853667/

The Good-News-Bad-News Basics of Fatty Liver Disease and NASH

There's some promising news about a hormone therapy for nonalcoholic steatohepatitis (NASH). Read on, but first, let's put things into context with some practical, real-life background stuff... How was your…

Continue Reading The Good-News-Bad-News Basics of Fatty Liver Disease and NASH
NASH: Get to Know Your Liver, and the Diseases that Can Affect It
https://pixabay.com/en/thistles-flower-marianum-plants-1039039/

NASH: Get to Know Your Liver, and the Diseases that Can Affect It

Liver disease has many causes and last month, March was Liver Disease Awareness month in Canada. Yes, Canada. That country with the handsomest Prime Minister... ever. (*Sigh*) But I digress. In…

Continue Reading NASH: Get to Know Your Liver, and the Diseases that Can Affect It
NASH and NAFLD: The Truth Behind Real Science Supports Permanent Weight Loss
[Source: Pixabay.com]

NASH and NAFLD: The Truth Behind Real Science Supports Permanent Weight Loss

Lying in bed this spectacularly beautiful fall Sunday morning—with my gently-snoring cat, Thelma, I feel so relaxed gazing out the window, watching ruby red leaves fluttering in the wind. But…

Continue Reading NASH and NAFLD: The Truth Behind Real Science Supports Permanent Weight Loss